<DOC>
	<DOC>NCT00782509</DOC>
	<brief_summary>This primary objective of this study is to compare two doses of BI 1744 CL inhalation solution delivered by the RespimatÂ® inhaler once daily to placebo in patients with chronic obstructive pulmonary disease (COPD).</brief_summary>
	<brief_title>12 / 48 wk Pivotal PFT vs PBO in COPD II</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<criteria>Inclusion criteria: All patients must have a diagnosis of chronic obstructive pulmonary disease Male or female patients, 40 years of age or older Patients must be current or exsmokers with a smoking history of more than 10 pack years Post bronchodilator FEV1 &lt;80% predicted and postbronchodilator FEV1/FVC &lt;70% Exclusion criteria: Patients with a significant disease other than COPD Patients with a history of asthma Patients with any of the following conditions: a history of myocardial infarction within 1 year of screening visit (Visit 1) unstable or lifethreatening cardiac arrhythmia. have been hospitalized for heart failure within the past year. known active tuberculosis a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed) a history of lifethreatening pulmonary obstruction a history of cystic fibrosis</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>